Agri-Chemical制造商拜耳宣布,它是从美国草坪和园林市场中除去基于草甘膦的除草剂,截至2023年。

该公司,该公司收购了流行的综合Weedkiller品牌作为其收购Monsanto的一部分,因此必须应对其安全性的昂贵的诉讼,并在美国法院找到追随者声称接触化学品的园丁造成了它们制定一种癌症,非霍奇金的淋巴瘤。

拜耳票据解决现有索赔数十亿美元的票据,该公司 - 仍继续捍卫草甘膦的安全 - 宣布它将用依赖替代活跃的新配方取代美国的草甘膦产品。配料。

“As the vast majority of claims in the litigation come from lawn and garden market users, this action largely eliminates the primary source of future claims beyond an assumed latency period," said Bayer. "There will be no change in the availability of the company’s glyphosate formulations in the US professional and agricultural markets.

“此外,该公司将与EPA讨论关于Roundup标签,其目标是向用户提供更多信息,以便为确保更加明智的购买和应用决策提供更多信息,”拜耳结束。

But with the US legal system now awash with case law precedent enabling sufferers of Non-Hodgkin’s lymphoma to trace their illness back to exposure to Roundup, Bayer has had to set aside $4.5billion to meet the cost of the backlog of cases yet to arise, on top of the $10.9billion already paid out. Meanwhile, a new ecosystem of campaigners and companies testing for glyphosate residues, or certifying products glyphosate-free, has sprung up to generate income from the absence of the chemical.

亨利·罗兰的导演项目来自侦查项目,欢迎拜耳宣布:“这是一场比例从草坪和园林市场中去除草甘膦的一场比赛,但这只是一个更大的战争的一部分。我们必须记住,这不会在美国和世界各地的更多金额中停止在公园,学校和我们的粮食作物中喷洒的草甘膦。

“现在是时候全球化学品并用安全的替代方案替换它。”